Kiadis to present at the Virtual European Biotech Investor Day 2020
17 Junho 2020 - 02:30AM
Kiadis to present at the Virtual European Biotech Investor Day 2020
Amsterdam, The Netherlands, June 17, 2020 –
Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam
and Brussels: KDS), a clinical stage biopharmaceutical
company, today announces that Kiadis will present at the Virtual
European Biotech Investor Day 2020 hosted by Solebury Trout,
Goodwin, Deutsche Bank and Nasdaq on Thursday, June 25, 2020 at
1:30pm EDT.
The presentation will be webcast live and may be accessed by
visiting the "For Investors" section of the Company's website under
the "Events and Presentations" tab at https://www.kiadis.com/. A
replay of the webcast will be available for 60 days.
Date: Thursday, June 25, 2020
Time: 1:30pm EDTWebcast:
https://www.webcaster4.com/Webcast/Page/2408/35385
Kiadis Contacts:
Kiadis:Maryann
Cimino, Sr. Manager, Corporate AffairsTel. +1 617 710
7305m.cimino@kiadis.com |
Optimum Strategic
Communications:Mary Clark, Supriya MathurTel: +44 203 950
9144David Brilleslijper (Amsterdam)Tel: +31 610 942
514kiadis@optimumcomms.com |
Dutch Translation/Nederlandse vertaling
Kiadis Pharma nv (‘Kiadis’) (Euronext
Amsterdam en Brussel: KDS), een biofarmaceutisch bedrijf
gericht op onderzoek in de klinische fase, kondigt aan dat het zal
presenteren op de Virtual European Biotech Investor Day 2020
georganiseerd door Solebury Trout, Goodwin, Deutsche Bank en Nasdaq
op donderdag 25 juni 2020 om 13.30 uur EDT.
De presentatie wordt live uitgezonden en kan worden bekeken via
het tabblad ‘For Investors’ door op het subtabblad ‘Events and
Presentations’ te klikken op de website van de onderneming:
https://www.kiadis.com/. Een herhaling van de webcast blijft 60
dagen beschikbaar.
Datum: Donderdag 25 juni 2020
Tijdstip: 13:30 uur EDTWebcast:
https://www.webcaster4.com/Webcast/Page/2408/35385
Dit persbericht vormt een vertaling van het
gepubliceerde Engelstalige persbericht. Bij eventuele verschillen
is de tekst van het Engelstalige persbericht altijd
bepalend.
About Kiadis’ K-NK-Cell Therapies Kiadis’
NK-cell programs consist of off-the-shelf and haplo donor cell
therapy products for the treatment of liquid and solid tumors as
adjunctive and stand-alone therapies.
The Company’s NK-cell PM21 particle technology enables improved
ex vivo expansion and activation of anti-cancer cytotoxic NK-cells
supporting multiple high-dose infusions. Kiadis’ proprietary
off-the-shelf NK-cell platform is based on NK-cells from unique
universal donors. The Kiadis off-the-shelf K-NK platform can make
NK-cell therapy product rapidly and economically available for a
broad patient population across a potentially wide range of
indications.
Kiadis is clinically developing K-NK003 for the treatment of
relapse/refractory acute myeloid leukemia. The Company is also
developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About KiadisFounded in 1997, Kiadis is building
a fully integrated biopharmaceutical company committed to
developing innovative therapies for patients with life-threatening
diseases. With headquarters in Amsterdam, the Netherlands, and
offices and activities across the United States, Kiadis is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis is listed on the regulated market of Euronext Amsterdam
and Euronext Brussels since July 2, 2015, under the symbol KDS.
Learn more at www.kiadis.com.
Forward Looking Statements Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current
expectations and projections about future events. By their nature,
forward-looking statements involve a number of known and unknown
risks, uncertainties and assumptions that could cause actual
results, performance, achievements or events to differ materially
from those expressed, anticipated or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance, achievements or
results to differ significantly from any anticipated or implied
development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, Kiadis expressly disclaims any obligation
or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.